Sol-Gel Technologies Ltd.
SLGL$243M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNESS ZIONA34 employees
Drugs in Pipeline
8
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
SLGL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
S6G5T-8
Acne Vulgaris
S6G5T-3
Acne Vulgaris
Patidegib Topical Gel, 2%
Basal Cell Nevus Syndrome
S5G4T-2
Papulopustular Rosacea
S5G4T-1
Papulopustular Rosacea
5-FU Cream
Actinic Keratosis (AK)
Patidegib Topical Gel
Gorlin Syndrome
DER 45 EV
Rosacea
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
S6G5T-8 | Phase 3 | Acne Vulgaris | - | - |
S6G5T-3 | Phase 3 | Acne Vulgaris | - | - |
Patidegib Topical Gel, 2% | Phase 3 | Basal Cell Nevus Syndrome | - | - |
S5G4T-2 | Phase 3 | Papulopustular Rosacea | - | - |
S5G4T-1 | Phase 3 | Papulopustular Rosacea | - | - |
5-FU Cream | Phase 3 | Actinic Keratosis (AK) | - | - |
Patidegib Topical Gel | Phase 3 | Gorlin Syndrome | - | - |
DER 45 EV | Phase 2 | Rosacea | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply